Articles

Poll

Podcasts

Slideshows

Videos

2024 was a historic year in hepatology, characterized by notable hepatic FDA approvals, pipeline developments, new WHO HBV guidelines, and more.

Hepatology Year in Review: 2024

Resmetirom made history when it became the first and only FDA-approved MASH drug in 2024, but the pipeline continues to show promise heading into 2025.

Headway in Hepatology: Resmetirom’s Historic FDA Approval, What’s Next in MASH

Patients with PSC had worse death, transplant, liver-related mortality, and liver-related decompensation outcomes than PBC and autoimmune hepatitis.

PSC Linked to Worse Transplant, Mortality Outcomes Than PBC, Autoimmune Hepatitis

The ML model exhibited better predictive performance than previous traditional HCC models in patients with chronic HBV on long-term antiviral therapy.

Machine Learning Model Accurately Predicts Long-Term HCC Risk in Patients with HBV

The phase 2b/3 NAVIGATE trial missed its primary endpoint for the prevention of varices in patients with MASH cirrhosis and portal hypertension.

Belapectin Misses Primary Endpoint in Phase 3 MASH Cirrhosis, Portal Hypertension Trial

Retransplantation outcomes were similar or better in patients with PSC compared with patients with other liver disease etiologies.

New Data Supports Liver Retransplantation for Patients with PSC Recurrence

Clark reviews open-label extension data from the phase 2b SEQUOIA study of fazirsiran for AATD liver disease.

Virginia Clark, MD: Understanding Fazirsiran’s Potential in AATD Liver Disease

The Boxed Warning is based on the FDA’s review of a postmarketing case of serious liver injury with fezolinetant reported to the FAERS database.

FDA Adds Boxed Warning to Fezolinetant (Veozah) for Liver Injury Risk

Real-world data from 18,710 MASH patients highlight the impact of comorbidities, biomarkers, and region on mortality, with 70% of deaths CVD-related.

Study Highlights Real-World Mortality Rates, Factors Increasing Mortality Risk in MASH 

Machine learning models improve accuracy in detecting MASH with F2-F3 fibrosis, surpassing noninvasive tests in sensitivity, specificity, and predictive value.

Machine-Learning Models Could Help ID MASH Patients Considered Candidates for Resmetirom

Alpha-1 antitrypsin deficiency

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.